Lymphangioleiomyomatosis (LAM) is a rare, slowly progressive neoplasm that causes gradual but often life-threatening cystic destruction of the lung. Advances in our understanding of the molecular and cellular pathogenesis have LAM have identified a number of promising targets for testing in therapeutic trials. However, the design, prioritization, organization, and implementation of clinical trials in rare lung diseases poses unique challenges, including geographically disperse populations, sluggish enrollment, off- label drug use, burdensome regulations, and paucity of validated surrogate endpoints.
Get full access to this article
View all access options for this article.
References
1.
McCormackFX. Lymphangioleiomyomatosis: A clinical update. Chest 1, 2008; 33:507–516.
2.
RyuJH, MossJ, BeckGJet al.The NHLBI lymphangioleiomyomatosis registry: Characteristics of 230 patients at enrollment. Am J Respir Crit Care Med, 2006; 173:105–111.
3.
JuvetSC, McCormackFX, KwiatkowskiDJ, DowneyGP. Molecular pathogenesis of lymphangioleiomyomatosis: Lessons learned from orphans. Am J Respir Cell Mol Biol, 2007; 36:398–408.
4.
BisslerJJ, McCormackFX, YoungLRet al.Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med, 2008; 358:140–151.
5.
CrinoPB, NathansonKL, HenskeEP. The tuberous sclerosis complex. N Engl J Med, 2006; 355:1345–1356.
6.
ItoN, RubinGM. gigas, a Drosophila homolog of tuberous sclerosis gene product-2, regulates the cell cycle. Cell, 1999; 96:529–539.
7.
PotterCJ, HuangH, XuT. Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell, 2001; 105:357–368.
YuJ, HenskeEP. Estrogen-induced activation of mammalian target of rapamycin is mediated via tuberin and the small GTPase ras homologue enriched in brain. Cancer Res, 2006; 66:9461–9466.
10.
YuJ, AstrinidisA, HowardS, HenskeEP. Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways. Am J Physiol Lung Cell Mol Physiol, 2004; 286:L694–L700.
ThoreenCC, SabatiniDM. Rapamycin inhibits mTORC1, but not completely. Autophagy, 2009; 5:725–726.
13.
YuJJ, RobbVA, MorrisonTAet al.Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc Natl Acad Sci USA, 2009; 106:2635–2640.
14.
ZheX, YangY, JakkarajuS, SchugerL. Tissue inhibitor of metalloproteinase-3 downregulation in lymphangioleiomyomatosis: Potential consequence of abnormal serum response factor expression. Am J Respir Cell Mol Biol, 2003; 28:504–511.
15.
HayashiT, FlemingMV, Stetler–StevensonWGet al.Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis. Hum Pathol, 1997; 28:1071–1078.
16.
MatsuiK, TakedaK, YuZX, TravisWD, MossJ, FerransVJ. Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med, 2000; 124:267–275.
17.
ZuckerS, CaoJ, ChenWT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene, 2000; 19:6642–6650.
18.
BittmannI, DoseTB, MullerC, DienemannH, VogelmeirC. Lymphagioleiomyomatosis: Recurrence after single lung transplantations. Hum Pathol, 1997; 26:1420–1423.
19.
KarbowniczekM, AstrinidisA, BalsaraBRet al.Recurrent lymphangiomyomatosis after transplantation: Genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med, 2003; 167:976–982.
20.
HenskeEP. Metastasis of benign tumor cells in tuberous sclerosis complex. Genes Chromosomes Cancer, 2003; 38:376–381.
21.
LongacreTA, HendricksonMR, KappDS, TengNN. Lymphangioleiomyomatosis of the uterus simulating high-stage endometrial stromal sarcoma. Gynecol Oncol, 1996; 63:404–410.
22.
CrooksDM, Pacheco–RodriguezG, DeCastroRMet al.Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc Natl Acad Sci USA, 2004; 101:17462–17467.
23.
BernerA, FranzenS, HeiloA. Fine needle aspiration cytology as a diagnostic approach to lymphangioleiomyomatosis. A case report. Acta Cytol, 1997; 41:877–879.
24.
KamitaniT, YabuuchiH, SoedaHet al.A case of lymphangioleiomyomatosis affecting the supraclavicular lymph nodes. J Comput Assist Tomogr, 2006; 30:279–282.
25.
KumasakaT, SeyamaK, MitaniKet al.Lymphangiogenesis-mediated shedding of LAM cell clusters as a mechanism for dissemination in lymphangioleiomyomatosis. Am J Surg Pathol, 2005; 29:1356–1366.
26.
KumasakaT, SeyamaK, MitaniKet al.Lymphangiogenesis in lymphangioleiomyomatosis: Its implication in the progression of lymphangioleiomyomatosis. Am J Surg Pathol, 2004; 28:1007–1016.
27.
SeyamaK, KumasakaT, SoumaSet al.Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat Res Biol, 2006; 4:143–152.
28.
YoungLR, InoueY, McCormackFX. Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis. N Engl J Med, 2008; 358:199–200.
29.
GoncharovaEA, GoncharovDA, LimPN, NoonanD, KrymskayaVP. Modulation of cell migration and invasiveness by tumor suppressor TSC2 in lymphangioleiomyomatosis. Am J Respir Cell Mol Biol, 2006; 34:473–480.
30.
HuberS, BrunsCJ, SchmidGet al.Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int, 2007; 71:771–777.
31.
KobayashiS, KishimotoT, KamataS, OtsukaM, MiyazakiM, IshikuraH. Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis. Cancer Sci, 2007; 98:726–733.
32.
KenersonH, DundonTA, YeungRS. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Pediatr Res, 2005; 57:67–75.
SchmithorstVJ, AltesTA, YoungLRet al.Automated algorithm for quantifying the extent of cystic change on volumetric chest CT: Initial results in lymphangioleiomyomatosis. AJR Am J Roentgenol, 2009; 192:1037–1044.
35.
GriggsRC, BatshawM, DunkleMet al.Clinical research for rare disease: Opportunities, challenges, and solutions. Mol Genet Metab, 2009; 96:20–26.
36.
Taveira–DaSilvaAM, SteagallWK, MossJ. Lymphangioleiomyomatosis. Cancer Control, 2006; 13:276–285.
37.
DaviesDM, JohnsonSR, TattersfieldAEet al.Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med, 2008; 358:200–203.
38.
TashkinDP, ElashoffR, ClementsPJet al.Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med, 2006; 354:2655–2666.
39.
KinderBW, ShermanAC, YoungLR, HagamanGT, OprescoN, ByrnesS, McCormackFX. Predictors for clinical trial participation in the rare lung disease lymphangioleiomyomatosis. Respir Med, 2009December3Epub ahead of print.
